• PTC Therapeutics projects 2026 total revenue of $1.29 billion–$1.32 billion, with operating expenses of $680 million–$720 million.
• Product revenue guidance of $960 million–$990 million represents 64%–69% year-over-year growth.
• Sephience generated $458 million in year-to-date global revenue during its first full launch year.
• Cash totaled $2.1 billion, with cash flow breakeven targeted for the year.
• The ST-920 gene therapy application for accelerated approval in Fabry disease is expected to be completed in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.